G protein-biased ligands for GLP-1R have been shown to enhance insulin secretion in mouse models of type 2 diabetes without producing nausea, a common adverse effect of GLP-1R agonists, thus allowing higher doses to be used. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.